|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
749.86 million
|
|
CAGR
(2023-2028)
|
4.67%
|
|
Fastest
Growing Segment
|
Therapeutics
|
|
Largest
Market
|
Asia-Pacific
|
Market Overview
Global Antithrombin Market has valued at USD 749.86
million in 2022 and is anticipated to project impressive growth in the forecast
period with a CAGR of 4.67% through 2028. The global antithrombin market
encompasses the pharmaceutical and biotechnology industry's efforts to produce
and distribute antithrombin products. Antithrombin is a naturally occurring
protein in the blood that plays a crucial role in preventing excessive blood
clotting. Dysfunctional antithrombin levels can lead to thromboembolic
disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and
disseminated intravascular coagulation (DIC). Therefore, antithrombin products
are used to treat and prevent these conditions.
Key Market Drivers
Increasing Prevalence of Thrombotic Disorders
Thrombotic disorders, characterized by the
formation of dangerous blood clots within the circulatory system, pose a
significant threat to public health worldwide. As the incidence of these
disorders continues to climb, so does the demand for effective treatments.
Among these treatments, antithrombin products are emerging as a crucial player,
playing a vital role in preventing and managing thrombotic events.
Thrombotic disorders encompass a range of
conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE),
stroke, and disseminated intravascular coagulation (DIC). These disorders can
lead to life-threatening complications, including organ damage and death. The
World Health Organization (WHO) identifies thrombosis as a major contributor to
global morbidity and mortality.
As the global population ages, the risk of
thrombotic events increases. Advanced age is a significant risk factor for
thrombosis due to changes in the vascular system and decreased mobility. Modern
sedentary lifestyles, characterized by prolonged sitting and limited physical
activity, are associated with an increased risk of thrombotic events,
especially DVT. Obesity is a known risk factor for thrombosis, as it leads to
inflammation and other metabolic changes that promote clot formation. Conditions
such as diabetes, cancer, and cardiovascular disease can increase the risk of
thrombotic events. Some individuals inherit genetic factors that make them more
susceptible to thrombosis. Major surgeries, including orthopedic,
cardiovascular, and gynecological procedures, carry a heightened risk of blood
clots. Antithrombin products are often used prophylactically in these
situations.
Antithrombin is a natural protein found in the
bloodstream that regulates the clotting process. It works by inhibiting several
clotting factors, including thrombin and factor Xa. When antithrombin levels
are deficient or dysfunctional, the risk of clot formation increases
significantly.
The growing number of individuals affected by
thrombotic disorders necessitates a greater demand for antithrombin products.
These products are essential for preventing and treating clot-related
complications. Antithrombin products are used prophylactically in high-risk
situations, such as before and after surgery, to prevent clot formation. As
surgical procedures become more common, the demand for antithrombin therapy
rises accordingly. Patients who experience thrombotic events often require
therapeutic antithrombin treatment to dissolve existing clots and prevent
further complications. The increasing prevalence of thrombotic disorders has
spurred research and development efforts to create more effective antithrombin
therapies, including recombinant products and novel formulations.
Aging Population Disorders
The world's population is aging at an unprecedented
rate, with a significant impact on healthcare systems globally. As people age,
they become increasingly vulnerable to various health conditions, including
thrombotic disorders, which involve the formation of blood clots within blood
vessels. This demographic shift towards an older population is a powerful
driver behind the growth of the global antithrombin market.
The aging of the global population is a
well-documented phenomenon. Advances in healthcare, improved living conditions,
and better access to medical care have led to longer life expectancies. As a
result, the world is witnessing a significant increase in the number of older
adults, particularly those aged 65 and older. This demographic shift has
profound implications for healthcare, including an increased prevalence of
age-related health conditions.
Aging leads to changes in the coagulation and
fibrinolysis pathways, making older individuals more susceptible to clot
formation. Age-related chronic conditions like cardiovascular disease,
diabetes, and cancer increase the risk of thrombosis. Older adults often have
decreased mobility, which can lead to the stagnation of blood flow and an
increased risk of clot formation. Older adults may undergo surgical procedures,
which can be associated with a higher risk of post-operative thrombosis.
As the population ages, the number of individuals
at risk of thrombotic disorders rises. This results in a greater demand for
antithrombin products for both prophylactic and therapeutic use. Older individuals may require surgery for
various medical conditions. These surgeries often necessitate the use of
antithrombin products to prevent post-operative clot formation. Antithrombin
therapy becomes crucial in managing thrombotic complications associated with
age-related chronic illnesses, such as cardiovascular diseases. The growing
demand for antithrombin products has incentivized pharmaceutical and
biotechnology companies to invest in research and development. This has led to
innovations in antithrombin therapies, including recombinant products and
improved formulations.
Advancements in Biotechnology and Pharmaceuticals
The global antithrombin market is experiencing a
transformative period, with advancements in biotechnology and pharmaceuticals
playing a pivotal role in its growth. Antithrombin, a crucial protein in
regulating blood clotting, has seen significant improvements in production
techniques, safety, and efficacy, which are driving its increasing relevance in
the healthcare sector.
Biotechnology has enabled the development of
recombinant antithrombin products. These are produced using genetically
engineered cells, which offer a controlled and consistent source of
antithrombin, reducing the risk of contamination and supply shortages. Innovative
purification methods have been developed to extract antithrombin from human
plasma more effectively. These techniques yield highly purified antithrombin
concentrates with minimal impurities, enhancing safety and efficacy. Biotechnology
has allowed for the development of novel antithrombin formulations, including
stable liquid preparations, which offer convenience and ease of administration
for patients and healthcare providers.
Research has led to a deeper understanding of the
mechanisms behind thrombotic disorders, enabling the development of more
targeted antithrombin therapies. These therapies have shown enhanced efficacy
in specific patient populations. Long acting antithrombin products have been
developed, reducing the frequency of administration for patients. This not only
improves patient compliance but also reduces the burden on healthcare systems. Ongoing
research has led to the development of antithrombin products with improved
safety profiles, reducing the risk of adverse events and allergic reactions.
As antithrombin products become more effective and
accessible, the demand for these therapies has grown, especially among
individuals at risk of thrombotic disorders. Advancements have expanded the
range of indications for antithrombin therapy, leading to its use in various
clinical scenarios, including perioperative settings, pregnancy-related
complications, and treatment-resistant thrombotic events. Improved
manufacturing processes and formulation stability have enabled the global
distribution of antithrombin products, making them more readily available to
patients in different regions.
Surgical Procedures and Medical Conditions
The global antithrombin market is witnessing
significant growth, driven in large part by the increasing prevalence of
surgical procedures and medical conditions that heighten the risk of
thrombosis. Antithrombin, a vital natural protein in the body's clotting
regulation system, has emerged as a critical element in preventing blood clots
during surgeries and managing thrombotic complications related to various
medical conditions.
Patients undergoing surgery are often immobile for
extended periods during and after the procedure, increasing the likelihood of
blood stasis and clot formation. Surgical trauma can damage blood vessels,
initiating the clotting process as part of the body's natural response to
injury. Anesthesia can affect blood flow, further increasing the risk of clot
formation. Longer surgeries carry a higher risk of clot formation due to
extended periods of immobility. Patients with preexisting medical conditions,
such as cancer or cardiovascular disease, are at an elevated risk of thrombotic
complications during surgery.
Antithrombin products are administered
prophylactically to surgical patients to reduce the risk of postoperative blood
clot formation. In certain high-risk surgeries, antithrombin may be used
intraoperatively to mitigate the risk of clot formation during the procedure.
Patients with conditions like atrial fibrillation
or coronary artery disease are at a higher risk of stroke and heart attack,
which may necessitate antithrombin therapy. Cancer patients have an elevated
risk of developing venous thromboembolism (VTE), which includes DVT and PE.
Antithrombin therapy is often part of VTE management. Conditions like
preeclampsia and eclampsia can lead to dangerous clotting events during
pregnancy. Antithrombin products may be used in the treatment of these
conditions. Some autoimmune diseases, such as antiphospholipid syndrome, can
increase the risk of thrombosis, warranting antithrombin therapy.
The rising number of surgical procedures and the
growing incidence of medical conditions associated with thrombosis have led to
an expanded market for antithrombin products. The use of antithrombin therapy
is no longer limited to just a few conditions; it has broadened to encompass a
wide range of clinical scenarios. Advances in manufacturing and distribution
have improved patient accessibility to antithrombin products, ensuring that
they are readily available when needed.
Download Free Sample Report
Key Market Challenges
Limited Awareness and Diagnosis
One of the primary challenges facing the
antithrombin market is the lack of awareness about thrombotic disorders. Many
individuals may not be aware of the symptoms or risk factors associated with
conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE). This can
result in delayed diagnosis and treatment, reducing the demand for antithrombin
therapies.
Variability in Diagnosis and Treatment Practices
Thrombotic disorders can present differently in
each patient, making diagnosis and treatment complex. Variability in diagnostic
practices and treatment approaches among healthcare providers can lead to
inconsistent use of antithrombin products. Standardized guidelines and
protocols are needed to ensure appropriate utilization of these therapies.
Regulatory Hurdles
The antithrombin market is subject to stringent
regulatory oversight, with regulatory agencies like the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) ensuring the
safety and efficacy of these products. Navigating regulatory pathways and
obtaining approvals for new antithrombin therapies can be time-consuming and
costly, slowing down product development and market entry.
Key Market Trends
Personalized Medicine and Precision Therapeutics
One of the most significant trends in the
antithrombin market is the shift towards personalized medicine. Advances in
genomics and molecular diagnostics are enabling healthcare providers to tailor
antithrombin therapies to individual patient profiles. This approach allows for
more targeted treatments, optimized dosages, and enhanced patient outcomes.
Novel Therapeutic Indications
Antithrombin therapies are traditionally associated
with thrombotic disorders such as deep vein thrombosis (DVT) and pulmonary
embolism (PE). However, ongoing research is expanding the range of therapeutic
indications. Antithrombin products are being explored for their potential in
conditions like sepsis, liver disease, and even as adjunct therapies in cancer
management.
Enhanced Formulations and Drug Delivery
Innovations in drug delivery methods and
formulation technologies are expected to make antithrombin therapies more
convenient and patient friendly. Long acting antithrombin products with
extended half-lives are being developed, reducing the frequency of administration
and improving patient compliance.
Segmental Insights
Usage Insights
Based on the category of Usage, it is anticipated
that the Therapeutics Segment will dominate the market share significantly
throughout the projected period. Antithrombin serves as a viable treatment
option in scenarios such as cardiac surgeries and genetic conditions like
hereditary antithrombin deficiency. This hereditary condition, also known as
antithrombin III deficiency or AT III deficiency, puts individuals at a higher
risk of developing blood clots and various heart ailments. Roughly 50% of those
afflicted with hereditary antithrombin deficiency will experience one or more
clotting events in their lifetime, typically occurring after adolescence,
necessitating appropriate treatment with antithrombin. As a result, this
segment is poised to be the driving force behind market growth during the study
duration.
Moreover, ongoing research efforts into the
treatment of various antithrombin deficiencies have the potential to expand the
applications of various drugs and bolster market expansion over the study
period. For instance, a research report published by the Thrombosis Update
journal in December 2021 recommended the use of low molecular weight heparin
(LMWH) in pregnancy, along with regular anti-Xa monitoring, to ensure that
women receive adequate antithrombotic therapy. Given the efficacy of LMWH in
activating antithrombin, individuals with antithrombin deficiency often require
substantial doses of LMWH. Consequently, with these new research findings, the
utilization of antithrombin drugs is expected to increase, further propelling
market growth during the study period.
Type Insights
Thrombolytic drugs are poised for substantial
growth in the Global Antithrombin Market during the forecast years for several
compelling reasons. Firstly, ongoing advancements in medical research and
technology have led to a deeper understanding of thrombotic disorders and their
treatment options. This increased knowledge is likely to result in a greater
utilization of thrombolytic drugs as a crucial component in the management of
various thrombotic conditions, thereby driving their demand. Secondly, the rising
prevalence of cardiovascular diseases and other conditions associated with
abnormal blood clot formation underscores the need for effective thrombolytic
therapies. As the global population ages and lifestyles evolve, the demand for
these drugs is expected to surge. Additionally, regulatory approvals and
endorsements from healthcare authorities for thrombolytic agents are
anticipated to provide a significant boost to their market presence.
Altogether, these factors are expected to fuel the growth of thrombolytic drugs
in the Global Antithrombin Market during the forecast years.
Download Free Sample Report
Regional Insights
In the forthcoming forecast period, the
Asia-Pacific region is poised to experience rapid growth. This upswing can be
attributed to the burgeoning adoption of innovative medical treatments and
techniques in developing nations like India and China, aimed at combatting a
spectrum of diseases. The escalating disposable incomes in these emerging
economies, coupled with their heightened capacity to invest in advanced
healthcare solutions, create fertile ground for market opportunities in the
Asia-Pacific region. Moreover, the increasing burden of an aging population,
along with a rising incidence of thrombosis-related ailments and ongoing
research into antithrombin deficiency within the region, is expected to be a
driving force behind market growth throughout the forecast period.
Notably, the expanding elderly population in India
plays a pivotal role in propelling the market in this region. According to data
from the NSO, the proportion of elderly individuals in India was projected to
reach 10.1% in 2021 and is forecasted to rise to 13.1% by 2031. With this
demographic shift, the risk of thrombosis increases substantially, resulting in
a heightened demand for antithrombin treatments, which, in turn, stimulates
market growth.
Furthermore, ongoing studies focusing on
antithrombin deficiency within the region are anticipated to bolster the
availability and utilization of antithrombin products, further augmenting
market expansion. For instance, a study published in Frontiers in Neurology in
June 2022 highlighted the various causes of antithrombin deficiency, including
inherited variants in the SERPINC1 gene. Consequently, diagnostic products such
as the SERPINC1 gene test are expected to gain traction, especially in
identifying the underlying causes of antithrombin deficiency-related arterial
thrombosis, such as ischemic stroke. These new research endeavors pertaining to
antithrombin deficiency are thus poised to boost the utilization of specific
diagnostic products and contribute to market growth over the forecast period.
Recent Developments
- In February 2022, Grifols initiated a partnership
with Endpoint Health, Inc. aimed at jointly advancing and bringing to market a
therapy for Sepsis utilizing Antithrombin III (AT-III). Under this
collaboration, Grifols will leverage its extensive industry know-how in
plasma-protein therapies and serve as the exclusive provider of AT-III, a vital
plasma protein used in the treatment of individuals with blood clotting
disorders.
- In the same month of February 2022, Techdow USA
Inc., a fully integrated manufacturer of generic injectable medications,
successfully introduced its Heparin Sodium Injection, USP, to the United States
market.
Key Market Players
- CSL Ltd
- Grifols
SA
- Takeda
Pharmaceutical Co Ltd
- Octapharma
AG
- LFB USA
- Endpoint
Health, Inc.
- Siemens
Healthcare GmbH
- Thermo
Fisher Scientific Inc
- Oy Medix
Biochemica Ab
|
By Usage
|
By Source
|
By Type
|
By Region
|
- Therapeutics
- Diagnostics
- Research
- Others
|
- Human
- Recombinant Goat Milk
- Others
|
- Anticoagulant
- Antiplatelet
- Thrombolytic Drugs
|
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Antithrombin Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Antithrombin Market, By Usage:
o Therapeutics
o Diagnostics
o Research
o Others
- Antithrombin Market, By Source:
o Human
o Recombinant Goat Milk
o Others
- Antithrombin Market, By Type:
o Anticoagulant
o Antiplatelet
o Thrombolytic Drugs
- Antithrombin Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Antithrombin
Market.
Available Customizations:
Global Antithrombin market report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Antithrombin Market is an upcoming report to
be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at [email protected]